Utilisation of hormone replacement therapy in the United Kingdom. A descriptive study using the general practice research database

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 111, Issue 4, 2004, Pages 369-376

  Bromley, S E ^a   De Vries, C S ^a,b   Farmer, R D T ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b Postgraduate Medical School   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; DYDROGESTERONE; ESTRADIOL; ESTROGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; NORGESTREL; PROGESTERONE; TIBOLONE;

ADULT; AGED; ARTICLE; DATA BASE; ESTROGEN THERAPY; FEMALE; GENERAL PRACTICE; HEALTH CARE UTILIZATION; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; OSTEOPOROSIS; PRIORITY JOURNAL; UNITED KINGDOM; COHORT ANALYSIS; MIDDLE AGED; PROSPECTIVE STUDY; STATISTICS; UTILIZATION REVIEW;

COHORT STUDIES; FAMILY PRACTICE; FEMALE; GREAT BRITAIN; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 1842452737     PISSN: 14700328     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2004.00082.x     Document Type: Article

References (28)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288(3):321-333.
2. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002;288(1):58-66.
3. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002;288(1):49-57.
4. Miller J, Chan BKS, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the US preventive services task force. Ann Intern Med 2002;136(9):680-689.
5. Grady D, Cummings SR. Postmenopausal hormone therapy for prevention of fractures. How good is the evidence? JAMA 2001;285(22):2909-2910.
6. Kuller LH. Hormone replacement therapy and coronary heart disease: a new debate. Cardiol Clin 1902;19(2):327-341.
7. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999;106:574-582.
8. Anonymous. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative group on hormonal factors in breast cancer. Lancet 1997;350(9084):1047-1059.
9. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti DB. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:305-313.
10. Lethaby A, Farquhar C, Sarkis A, Roberts H, Jepson R, Barlow D. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochr Database Syst Rev 2000;2.
11. Vihtamaki T, Savilahti R, Tuimala R. Why do postmenopausal women discontinue hormone replacement therapy. Maturitas 1999;33:99-105.
12. Albertazzi P, Di Micco R, Zanardi E. Tibolone: a review. Maturitas 1998;30:295-305.
13. The British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary 42. London: BMA and the Pharmaceutical Society of Great Britain, 2001.
14. Garcia RL, Perez GS. Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45(5):419-425.
15. Walley T, Mantgani A. The UK general practice research database. Lancet 1997;350(9084):1097-1099.
16. Perry J. Oxmis Problem Codes Primary Medical Care, Oxford: Headington, 1978.
17. NHS Management Executive. What are the Read Codes? http://www. doh.gov.uk/ipu/strategy/archive/1992/infrastr/read.pdf, 2002.
18. Van Staa T, Abenhaim L. The quality of information recorded on a database of primary care records: a study of hospitalizations due to hypoglycaemia and other conditions. Pharmacoepidemiol Drug Safety 1994;3:15-21.
19. Hollowell J. The general practice research database: quality of morbidity data. Popul Trends 1997;87:36-40.
20. Stata Statistical Software. College Station, Texas: Stata Corporation, 2001.
21. Lancaster T, Surman G, Lawrence M, et al. Hormone replacement therapy: characteristics of users and non-users in a British general practice cohort identified through computerised prescribing records. J Epidemiol Commun Health 1995;49(4):389-394.
22. Harris TJ, Cook DG, Wicks PD, Cappuccio FP. Ethnic differences in use of hormone replacement therapy: community based survey. BMJ 1999;319:610-611.
23. Lawrence M, Jones L, Lancaster T, Daly E, Banks E. Hormone replacement therapy: patterns of use studied through British general practice computerized records. Family Practice 1999;16(4):335-342.
24. Townsend J. Hormone replacement therapy: assessment of present use, costs, and trends. Br J Gen Pract 1998;48:955-958.
25. Whitlock EP, Johnson RE, Vogt TM. Recent patterns of hormone replacement therapy use in a large managed care organization. J Women's Health 1998;7(8):1017-1026.
26. Wysowski DK, Golden L, Burke L. Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstet Gynecol 1995;85(1):6-10.
27. Ellerington MC, Whitcroft SIJ, Whitehead MI. HRT: developments in therapy. Br Med Bull 1992;48(2):401-425.
28. Wilkes HC, Meade TW. Hormone replacement therapy in general practice: a survey of doctors in the MRC's general practice research framework. BMJ 1991;302(6788):1317-1320.